重型颅脑创伤后颅内压升高可被抗分泌因子抑制——一项先导研究
本先导研究纳入4例重型颅脑创伤(GCS<9)且颅内压监测提示难治性颅内高压的患者,在常规神经重症治疗基础上给予Salovum®(富含AF肽的蛋黄粉)100 mL每8小时一次、经鼻胃管或直肠给药2至3天。结果显示经直肠给药期间颅内压可获控制且血AF水平升高,未观察到归因于AF治疗或直肠给药的不良事件;作者认为AF可能成为针对创伤性脑水肿的新治疗选择。
要点
- 4例重型颅脑创伤(GCS<9)伴难治性颅内高压患者接受Salovum® 100 mL每8小时一次、2至3天。
- 经鼻胃管给药时Salovum®在胃内蓄积、胃排空受损致颅内压难以控制,遂改用直肠给药。
- 第3、4例经直肠给药期间颅内压可获控制,颅内压下降有统计学显著性并伴血AF水平升高。
核心结论
- 结果提示AF可作为创伤性脑水肿所致高颅内压的抑制因子,AF可能为临床实践中针对脑水肿提供新的治疗选择。
研究设计与样本
- 先导研究,纳入4例需神经重症监护及颅内压监测的重型颅脑创伤(GCS<9)且伴难治性颅内高压征象的患者。
- 在常规神经重症治疗基础上给予Salovum®(富含AF肽的市售蛋黄粉)100 mL每8小时一次、持续2至3天,经鼻胃管(患者1和2)或直肠管(患者2、3和4)给药。
- 持续记录颅内压,并以酶联免疫吸附试验(ELISA)测定血浆AF水平以确认Salovum®被适当吸收入血。
主要发现
- 前两例经鼻胃管给药时观察到Salovum®溶液在胃内蓄积、胃排空受损致颅内压难以控制,因此试验改为直肠给予Salovum®。
- 第3、4例均有广泛脑水肿的影像学征象,在直肠给予Salovum®期间颅内压可获控制。
- 颅内压下降有统计学显著性,并伴血AF水平升高。
- 未观察到可归因于AF治疗或Salovum®直肠给药途径的不良事件。
临床怎么用
- 作者认为AF可能为临床实践中针对脑水肿提供新的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Control of intracranial pressure (ICP) is a key element in neurointensive care for directing treatment decisions in patients with severe traumatic brain injury (TBI). The anti-inflammatory protein antisecretory factor (AF) has been demonstrated to reduce experimentally induced high ICP in animal models. This report describes the first steps to investigate the uptake, safety, and influence of AF for reduction of elevated ICP in patients with TBI in a clinical setting. METHOD: Four patients with severe TBI (Glasgow Coma Scale < 9) that required neurointensive care with ICP monitoring due to signs of refractory intracranial hypertension were investigated. One hundred milliliters of Salovum®, a commercially available egg yolk powder with high contents of AF peptides, was administrated either via nasogastric (patients 1 and 2) or rectal tube (patients 2, 3, and 4) every 8 h for 2 to 3 days as a supplement to the conventional neurointensive care. ICP was registered continuously. Plasma levels of AF were measured by enzyme-linked immunosorbent assay (ELISA) to confirm that Salovum® was absorbed appropriately into the bloodstream. RESULTS: In the first two patients, we observed that when delivered by the nasogastric route, there was an accumulation of the Salovum® solution in the stomach with difficulties to control ICP due to impaired gastric emptying. Therefore, we tested to administer Salovum® rectally. In the third and fourth patients, who both showed radiological signs of extensive brain edema, ICP could be controlled during the course of rectal administration of Salovum®. The ICP reduction was statistically significant and was accompanied by an increase in blood levels of AF. No adverse events that could be attributed to AF treatment or the rectal approach for Salovum® administration were observed. CONCLUSIONS: The outcomes suggest that AF can act as a suppressor of high ICP induced by traumatic brain edema. Use of AF may offer a new therapeutic option for targeting cerebral edema in clinical practice.
引用
- Gatzinsky K, Johansson E, Jennische E, et al. Elevated intracranial pressure after head trauma can be suppressed by antisecretory factor-a pilot study. Acta Neurochir (Wien). 2020. PMID: 32445122. doi:10.1007/s00701-020-04407-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。